RT Journal
A1 Hernandez AV
T1 No place for novel oral anticoagulants in current treatment of acute coronary syndromes: Comment on “use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome”
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD November 12
VO 172
IS 20
SP 1546
OP 1547
DO 10.1001/2013.jamainternmed.293
UL http://dx.doi.org/10.1001/2013.jamainternmed.293
AB 
In contrast to warfarin, novel oral anticoagulants (NOACs), such as direct thrombin inhibitors and anti-Xa, do not require monitoring and have minimal food and drug interactions. Moreover, compared with warfarin NOACs have demonstrated significant reductions in thrombotic events and lower rates of major bleeding events in patients having atrial fibrillation and in patients undergoing knee and hip surgery.3 In recent years, several phase 2 and phase 3 trials of NOACs for the treatment of patients with ACS have been published, with most of the patients receiving dual antiplatelet treatment. Although recent detailed review articles have described the pros and cons of the use of NOACs in ACS,4- 5 the available evidence has not been quantitatively summarized.